Alice T. Shaw

71.9k total citations · 19 hit papers
332 papers, 25.2k citations indexed

About

Alice T. Shaw is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alice T. Shaw has authored 332 papers receiving a total of 25.2k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Pulmonary and Respiratory Medicine, 255 papers in Oncology and 87 papers in Molecular Biology. Recurrent topics in Alice T. Shaw's work include Lung Cancer Treatments and Mutations (301 papers), Lung Cancer Research Studies (140 papers) and Colorectal Cancer Treatments and Studies (90 papers). Alice T. Shaw is often cited by papers focused on Lung Cancer Treatments and Mutations (301 papers), Lung Cancer Research Studies (140 papers) and Colorectal Cancer Treatments and Studies (90 papers). Alice T. Shaw collaborates with scholars based in United States, Italy and South Korea. Alice T. Shaw's co-authors include Ibiayi Dagogo‐Jack, Benjamin Solomon, Justin F. Gainor, Jeffrey A. Engelman, W. Marston Linehan, A. John Iafrate, Sai‐Hong Ignatius Ou, D. Ross Camidge, Gregory J. Riely and Tony Mok and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Alice T. Shaw

324 papers receiving 24.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour heterogeneity and resistance to cancer therapies

2017 2.4k citations Ibiayi Dagogo‐Jack, Alice T. Shaw profile →
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

2017 1.6k citations D. Ross Camidge, Alice T. Shaw et al. New England Journal of Medicine profile →
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Ryohei Katayama, Alice T. Shaw et al. profile →
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine profile →
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

2004 626 citations Alice T. Shaw, Tyler Jacks et al. profile →
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population

2009 526 citations Scott J. Rodig, Mari Mino–Kenudson et al. Clinical Cancer Research profile →
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. profile →
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

2017 487 citations Alice T. Shaw, Enriqueta Felip et al. profile →
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

2015 468 citations Daniel B. Costa, Alice T. Shaw et al. Journal of Clinical Oncology profile →
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

2015 462 citations Alice T. Shaw, D. Ross Camidge et al. profile →
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

2013 460 citations Justin F. Gainor, Mark M. Awad et al. Clinical Cancer Research profile →
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 412 citations Alice T. Shaw, Geoffrey Liu et al. profile →
Targeting ALK: Precision Medicine Takes on Drug Resistance

2017 369 citations W. Marston Linehan, Alice T. Shaw et al. Cancer Discovery profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations D. Ross Camidge, Tony Mok et al. Journal of Thoracic Oncology profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →
ALK-positive lung cancer: a moving target

2023 86 citations W. Marston Linehan, Alice T. Shaw et al. profile →

Peers

Countries citing papers authored by Alice T. Shaw

Since Specialization

Citations

This map shows the geographic impact of Alice T. Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice T. Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice T. Shaw more than expected).

Fields of papers citing papers by Alice T. Shaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice T. Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice T. Shaw. The network helps show where Alice T. Shaw may publish in the future.

Co-authorship network of co-authors of Alice T. Shaw

This figure shows the co-authorship network connecting the top 25 collaborators of Alice T. Shaw. A scholar is included among the top collaborators of Alice T. Shaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice T. Shaw. Alice T. Shaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Response and Resistance to RAS Inhibition in Cancer 2025 ·Cancer Discovery ·Richard Y. Ebright, Julien Dilly, Alice T. Shaw, Andrew J. Aguirre	4
2	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study breakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	118
3	Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study 2024 ·Lung Cancer ·Ibiayi Dagogo‐Jack, Alissa J. Cooper, (unknown), Justin F. Gainor, W. Marston Linehan, Lecia V. Sequist, Zofia Piotrowska, Subba R. Digumarthy, Mari Mino–Kenudson, Alona Muzikansky, Alice T. Shaw	1
4	Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 2023 ·Journal of Thoracic Oncology ·Ross A. Soo, Jean‐François Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, (unknown), Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao‐Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin Solomon	22
5	First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer breakdown → 2020 ·New England Journal of Medicine ·Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazières, Dong‐Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Benjamin Solomon	649
6	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity 2019 ·Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Marguerite Rooney, W. Marston Linehan, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw	112
7	OA15.01 Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial 2019 ·Journal of Thoracic Oncology ·Anna F. Farago, B.Y. Yeap, Rebecca S. Heist, Judith Marcoux, Deepa Rangachari, David A. Barbie, Elizabeth A. Kennedy, Mari Mino–Kenudson, Alice T. Shaw	1
8	Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks, Benjamin Levy, (unknown), Victoria M. Raymond, Anh T. Le, Christine E. Lee, Joseph A. Diaz, Saiama N. Waqar, W. Thomas Purcell, Dara L. Aisner, (unknown), Richard B. Lanman, Alice T. Shaw, Robert C. Doebele	114
9	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer 2018 ·Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Pablo Martínez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, Mark M. Awad	80
10	MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study 2018 ·Journal of Thoracic Oncology ·Todd M. Bauer, Alice T. Shaw, Melissa L. Johnson, Alejandro Navarro, Justin F. Gainor, Holger Thurm, Yazdi K. Pithavala, Antonello Abbattista, Enriqueta Felip	4
11	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies 2016 ·Journal of Thoracic Oncology ·Meghan Campo, David E. Gerber, Justin F. Gainor, Rebecca S. Heist, Jennifer S. Temel, Alice T. Shaw, Panos Fidias, Alona Muzikansky, Jeffrey A. Engelman, Lecia V. Sequist	71
12	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib 2015 ·Clinical Cancer Research ·Justin F. Gainor, Daniel Shao-Weng Tan, (unknown), Benjamin Solomon, (unknown), Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine R. Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw	135
13	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib 2014 ·Clinical Cancer Research ·Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw	222
14	Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer 2014 ·Clinical Cancer Research ·Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita	147
15	Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Zofia Piotrowska, Matthew J. Niederst, Mari Mino–Kenudson, Vicente Morales‐Oyarvide, Linnea Fulton, Elizabeth L. Lockerman, Emily Howe, Justin F. Gainor, P. Fidias, Rebecca S. Heist, Alice T. Shaw, J. A. Engelman, Lecia V. Sequist	12
16	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer 2013 ·Cancer Discovery ·Jim Sang, Jaime Acquaviva, Julie C. Friedland, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Qin Jiang, Liquan Xue, Christine M. Lovly, (unknown), Alice T. Shaw, Robert C. Doebele, Suqin He, Richard C. Bates, D. Ross Camidge, Stephan W. Morris, Iman El‐Hariry, David A. Proia	174
17	Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer? 2012 ·Clinical Cancer Research ·Adam Crystal, Alice T. Shaw	11
18	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress 2011 ·Proceedings of the National Academy of Sciences ·Alice T. Shaw, Monte M. Winslow, Margaret Magendantz, Chensi Ouyang, James A. Dowdle, Aravind Subramanian, Timothy A. Lewis, (unknown), Nicola Tolliday, Tyler Jacks	200
19	Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population breakdown → 2009 ·Clinical Cancer Research ·Scott J. Rodig, Mari Mino–Kenudson, Sanja Đačić, Beow Y. Yeap, Alice T. Shaw, Justine A. Barletta, Hannah Stubbs, (unknown), Neal I. Lindeman, Eugene J. Mark, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, A. John Iafrate, Lucian R. Chirieac	526
20	Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK breakdown → 2009 ·Journal of Clinical Oncology ·Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Subba R. Digumarthy, Daniel B. Costa, Rebecca S. Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott, Jeffrey Settleman, Susumu Kobayashi, Eugene J. Mark, Scott J. Rodig, Lucian R. Chirieac, Eunice L. Kwak, Thomas J. Lynch, A. John Iafrate	1463

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact